-
Something wrong with this record ?
Indoleamine 2,3-Dioxygenase (IDO) regulates Th17/Treg immunity in experimental IgA nephropathy
Y. Yang, K. Liu, Y. Chen, Y. Gong, Y. Liang
Language English Country Czech Republic
Document type Journal Article
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
ProQuest Central
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
- MeSH
- Th17 Cells immunology MeSH
- Cytokines metabolism MeSH
- Glomerulonephritis, IGA enzymology immunology MeSH
- Immunity * MeSH
- Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism MeSH
- Kidney injuries metabolism pathology MeSH
- Mice, Inbred BALB C MeSH
- T-Lymphocytes, Regulatory immunology MeSH
- Signal Transduction MeSH
- Animals MeSH
- Check Tag
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. Current studies have shown that the Th17/Treg immune balance may be involved in the occurrence of IgAN, but the exact mechanism is still unclear. Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyses degradation of tryptophan (Trp) through the kynurenine (Kyn) pathway; it can control inflammation and immune response by inducing Trp starvation. IDO may be a key molecule in regulating the Th17/Treg immune balance. However, it is not clear whether IDO is involved in the IgAN disease occurrence by regulating the Th17/Treg immune balance. In this study, an IgAN mouse model was established. The mice were intraperitoneally inoculated with IDO inhibitor 1-MT or agonist ISS-ODN to observe whether the IDO signalling pathway participates in the occurrence and development of IgAN by regulating the Th17/Treg immune balance. The results showed that IDO inhibitor 1-MT significantly increased renal injury and glomerular IgA accumulation and up-regulated Th17/Treg and Th17-related cytokine expression in IgAN mice, while ISS-ODN significantly decreased renal injury and glomerular IgA accumulation, down-regulated Th17/Treg expression and inhibited Th17-related cytokine expression in IgAN mice. In conclusion, IDO was involved in the occurrence and progress of IgAN by regulating the Th17/ Treg balance.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19047514
- 003
- CZ-PrNML
- 005
- 20200213135044.0
- 007
- ta
- 008
- 200205s2019 xr d f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)31464185
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Yang, Y. $u Department of Nephrology, Laboratory of Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, P. R. China
- 245 10
- $a Indoleamine 2,3-Dioxygenase (IDO) regulates Th17/Treg immunity in experimental IgA nephropathy / $c Y. Yang, K. Liu, Y. Chen, Y. Gong, Y. Liang
- 520 9_
- $a IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. Current studies have shown that the Th17/Treg immune balance may be involved in the occurrence of IgAN, but the exact mechanism is still unclear. Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyses degradation of tryptophan (Trp) through the kynurenine (Kyn) pathway; it can control inflammation and immune response by inducing Trp starvation. IDO may be a key molecule in regulating the Th17/Treg immune balance. However, it is not clear whether IDO is involved in the IgAN disease occurrence by regulating the Th17/Treg immune balance. In this study, an IgAN mouse model was established. The mice were intraperitoneally inoculated with IDO inhibitor 1-MT or agonist ISS-ODN to observe whether the IDO signalling pathway participates in the occurrence and development of IgAN by regulating the Th17/Treg immune balance. The results showed that IDO inhibitor 1-MT significantly increased renal injury and glomerular IgA accumulation and up-regulated Th17/Treg and Th17-related cytokine expression in IgAN mice, while ISS-ODN significantly decreased renal injury and glomerular IgA accumulation, down-regulated Th17/Treg expression and inhibited Th17-related cytokine expression in IgAN mice. In conclusion, IDO was involved in the occurrence and progress of IgAN by regulating the Th17/ Treg balance.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a IgA nefropatie $x enzymologie $x imunologie $7 D005922
- 650 12
- $a imunita $7 D007109
- 650 _2
- $a indolamin-2,3,-dioxygenasa $x metabolismus $7 D050503
- 650 _2
- $a ledviny $x zranění $x metabolismus $x patologie $7 D007668
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a regulační T-lymfocyty $x imunologie $7 D050378
- 650 _2
- $a buňky Th17 $x imunologie $7 D058504
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Liu, K. $u Department of Nephrology, Laboratory of Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, P. R. China
- 700 1_
- $a Chen, Y. $u Department of Nephrology, Laboratory of Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, P. R. China
- 700 1_
- $a Gong, Y. $u Department of Nephrology, Laboratory of Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, P. R. China
- 700 1_
- $a Liang, Y. $u Department of Nephrology, Laboratory of Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, P. R. China
- 773 0_
- $w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 65, č. 2 (2019), s. 101-108
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31464185 $y Pubmed
- 856 41
- $u https://fb.cuni.cz/file/5895/fb2019a0010.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 970 $c 89 $y p $z 0
- 990 __
- $a 20200205 $b ABA008
- 991 __
- $a 20200207110749 $b ABA008
- 999 __
- $a ok $b bmc $g 1493340 $s 1086234
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 65 $c 2 $d 101-108 $e - $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
- LZP __
- $b NLK118 $a Pubmed-20200205